Bausch+Lomb Results Presentation Deck

Top 10 Revenues (Includes FX Impact) Rank Product/Franchises 1 2 3 4 6 5 Bausch+Lomb UltraⓇ 7 8 9 Ocuvite® + PreserVision® Surgical Consumables¹ SofLens Biotrue ONEday 10 Ⓡ Surgical Equipment¹ Surgical Implantables¹ Lumify® Franchise renu® Biotrue® Solutions Franchise BAUSCH+ LOMB 3Q23 $104 M $93M $60M $51M $51M $47M $45M $44M $43M $42M 2Q23 $104M $102M $59M $49M $42M $46M $47M $43M $43M $49M 1Q23 $81M $95M $60M $52M $51M $44M $44M $38M $42M $35M FY22 $387M $359M $246M $201M $177M $171M $188M $131M $176M $153M 4Q22 $114M $94M $62M $50M $43M $45M $49M $35M $47M $37M 1. As of the first quarter of 2023, certain products were recategorized across the consumables, implantables and equipment product categories. This change was made as management believes this better aligns these products in their respective categories. Prior period presentations of product categories have been conformed to current product category structure to allow investors to evaluate results between periods on a consistent basis. 3Q22 $98M $85M $62M $53M $46M $42M $45M $30M $44M $39M 24

View entire presentation